Back to results
US 6,887,848 B2Granted
Vascular endothelial growth factor variants
AssigneeScios, Inc.
InventorsN. Stephen Pollitt, Judith A. Abraham
Life of this patent
Estimating the term…
Abstract
The invention is directed to a method of enhancing the biological activity of vascular endothelial growth factors (VEGF). The invention further concerns certain VEGF variants having enhanced biological activity, methods and means for preparing these variants, and pharmaceutical compositions comprising them. In a further aspect, the invention concerns methods of treatment using, and articles of manufacture containing such VEGF variants.
Claims17
A method of inducing angiogenesis comprising:
- administering an effective amount of a vascular endothelial growth factor VEGF (hVEGF121) variant to a patient in need thereof, wherein the VEGF variant comprises amino acids 27-147 of SEQ ID NO:2, and
- wherein SEQ ID NO:2 has been altered by an amino acid substitution or deletion at (position 142 of SEQ ID NO:2);
- and
- wherein SEQ ID NO:2 has been altered by an amino acid substitution or deletion at position 101, 102, or 103, such that the variant is not glycosylated, said variant having at least 85% sequence identity with hVEGF121 polypeptide (amino acids 27-147 of SEQ ID NO:2),
- whereby angiogenesis is induced by the VEGF variant administered.
2 more elements
Dependencies are inferred from the claim text.